Alnylam Pharmaceuticals Inc., of Cambridge, Mass., initiated its phase III open-label extension study, APOLLO-OLE, with patisiran, its RNAi candidate targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis in patients with familial amyloidotic polyneuropathy, or FAP.